BioAge Labs Inc. (NASDAQ: BIOA) is a Healthcare company (Biotechnology) with a market capitalization of $192M. The Maz Rating grades it against the other companies in its sector.
BioAge Labs Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $5.10, BioAge Labs Inc. trades at 22.3x sales and 0.7x book value. Over the last twelve months it generated about $9M of revenue and a net loss of $96M. It runs a gross margin of 99.3%, an operating margin of -1401.8% and a net margin of -1253.6%. It shows return on equity of -31.4%, return on invested capital of -34.5% and a free cash flow yield of -53.7%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 15.51. Over the past 52 weeks the share price ranged from $4.81 to $25.96, with a beta of 0.94.
BioAge Labs Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 6 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, BioAge Labs Inc. (BIOA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 108.0% / 30% · Interest income / Revenue 1138.6% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 87.0% / 33% · Receivables / Mkt Cap (36m) 0.88% / 49% · Interest income / Revenue 1138.6% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 87.0% / 33.33% · Receivables / Mkt Cap (24m) 0.88% / 33.33% · Interest income / Revenue 1138.6% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.57% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 86.9% / 33.33% · Receivables / Avg Assets (4Q) 0.34% / 33.33% · Interest income / Revenue 1138.6% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 77.1% / 33.33% · (Cash+Recv) / Total Assets 77.9% / 33.33% · Interest income / Revenue 1138.6% / 5% | Fail |
No. As of September 2026, BioAge Labs Inc. (BIOA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. BioAge Labs Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 1138.6% of each dividend: BioAge Labs Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.